A phase 2 study found that retreating older patients with relapsed multiple myeloma using daratumumab, lenalidomide, and dexamethasone (DRd) remained effective even after previous daratumumab-based treatment.
The GMMG-DADA trial enrolled 67 transplant-ineligible patients with a median age of 74, including many with severe kidney disease who are often excluded from clinical trials.
During first-line treatment, nearly 70% of patients achieved a very good partial response or better, while the overall response rate reached 83.9%. More than half of the evaluated patients had no detectable minimal residual disease, and the median progression-free survival was 29.9 months.
Among 27 patients whose disease later returned, DRd retreatment produced a 77% overall response rate. Patients whose cancer relapsed after 12 months responded best, with an 88% response rate, while those relapsing within 12 months had a 60% response rate.
The treatment’s safety profile was consistent with previous studies, with no new safety concerns reported during retreatment.